Consultant
Santa Fe, NM
Robert Marcus, MD
Biography:
Robert Marcus, M.D., joined the US Affiliate of Eli Lilly & Company in 2001 to support Lilly’s program in Osteoporosis and Skeletal Medicine. Prior to coming to Lilly, Dr. Marcus had completed almost 30 years in Academic Medicine, the last two decades of which were at Stanford University School of Medicine, where he is Professor Emeritus of Medicine, and at the Veterans Affairs Medical Center, Palo Alto, California, where he served as Director of the Aging Study Unit of the Geriatrics Research, Education, & Clinical Center from 1982-2001.
Dr. Marcus enjoyed a long career as a clinical investigator in the fields of Bone & Mineral Metabolism and Osteoporosis Medicine. His own research interests included diagnosis and therapy of primary hyperparathyroidism, interactions of the parathyroid-vitamin D axis with estrogen, age-related changes in the growth hormone-IGF axis, effects of growth hormone replacement for older men and women, metabolic and musculoskeletal effects of resistance exercise in older men and women, adolescent bone acquisition and osteoporosis therapeutics.
Dr. Marcus’ laboratory was a study site for many of the large pivotal clinical trials in the osteoporosis field. These include the NIH Post-menopausal Estrogen/Progestin Interventions Trial(PEPI), Merck’s Fracture Intervention Trial (FIT), Lilly’s Multiple Outcomes of Raloxifene Intervention (MORE) and Lilly’s registration trial of recombinant PTH(1-34) in the treatment of post-menopausal women with osteoporosis. Dr. Marcus has published more than 150 research papers, editorials and reviews, and is the Chief Editor of the award-winning research text,”OSTEOPOROSIS,” published by Elsevier and currently in its third edition. Dr. Marcus served as President of the American Society for Bone & Mineral Research in 2000-2001. He retired from Lilly in 2008.